自体造血干细胞移植治疗多发性骨髓瘤

The effect of autologous stem cell transplantation in multiple myeloma

自体造血干细胞移植(ASCT)治疗多发性骨髓瘤进展较大。与常规方案相比,ASCT 提高了患者的完全缓解(CR)、无事件生存(EFS)和总生存率(OS)。高龄、肾衰竭并非 ASCT 的禁忌证。双次ASCT 可提高 CR 率,对长期 EFS 率、OS 率影响仍需观察。改进预处理方案、选择移植时机、改进移植后巩固治疗可以提高疗效。

There are many progresses in the therapy of MM with ASCT. ASCT improves the ratio of CR,EFS and OS,compared with conventional chemotherapy.Myeloma patients with renal failure or old age also can be candidate for ASCT.Tandem autologous transplantation improves the ratio of CR. Its impact to long-term EFS and OS still need to be judged.To improve conditional project,to choose suitable time,and- toselect consolidation schedule can boost therapeutic effect.